Clinical Trials

Hodgkin Disease

NCT06812858 2025-08-19

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Phase 2 Recruiting

83 enrolled

Hodgkin Disease

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Phase 1/2 Completed

50 enrolled 10 charts

Hodgkin Disease

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03179917 2025-05-07

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Phase 2 Active not recruiting

22 enrolled

Hodgkin Disease

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

71 enrolled

Phase EARLY_PHASE1 Active not recruiting

Hodgkin Disease

NCT04134325 2025-04-16

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

10 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease

NCT06045195 2025-04-06

Pembro-FLASH

40 enrolled

Phase 2 Active not recruiting

Hodgkin Disease

NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

8 enrolled

Hodgkin Disease

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Hodgkin Disease, Recurrence

NCT02453594 2024-10-29

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Phase 2 Completed

211 enrolled 22 charts

Hodgkin Disease

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03331731 2023-08-21

PLIMATH

27 enrolled

Hodgkin Disease

NCT03077828 2023-06-02

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

43 enrolled 9 charts

Hodgkin Disease

NCT03226249 2023-06-02

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

30 enrolled 10 charts

Hodgkin Disease

NCT03776864 2023-05-03

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 8 charts

Hodgkin Disease

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

DermatologicHead & NeckLymphoidThoracic

159 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02875067 2020-08-14

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Phase 1/2 Terminated

6 enrolled 5 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03471351 2019-12-27

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

2 enrolled

Hodgkin Disease

NCT02665650 2019-05-16

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1 Completed

30 enrolled

Hodgkin Disease

NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1/2 Withdrawn